Page 24 - Martin Shkreli Teaching Guide

willing to cover this by passing the blame onto the
insurance companies as they fight with the medical

fraternity over copay responsibilities.

Shkreli’s MSMB company was less than successful and
his ventures into senior management at Retrophin,

Turing and KaloBios was likewise short lived and

contentious. In some senses he acted as a corporate

raider stepping in acquiring drugs to hike their prices.